# PD1 and PARP for Maintenance Therapy in NSLLC

> **NCT05392686** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 52 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** PD-1 inhibitor
- **DRUG:** PARP inhibitor

## Key facts

- **NCT ID:** NCT05392686
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-20
- **Primary completion:** 2022-06-21
- **Final completion:** 2025-04-01
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05392686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05392686, "PD1 and PARP for Maintenance Therapy in NSLLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05392686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*